ImmunoCellular (IMUC) +7% AH after announcing Andrew Gengos, until recently the CEO of private Neuraltus Pharmaceuticals, is its new CEO. Chief scientific officer John Yu had been serving as interim CEO since August, when former chief Manish Singh stepped down.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs